Browsing Tag
Idiopathic pulmonary fibrosis
18 posts
Contineum Therapeutics (NASDAQ: CTNM) shares slump after PIPE-307 fails to show efficacy in multiple sclerosis trial
PIPE-307 failed to meet efficacy endpoints in RRMS Phase 2, sending Contineum Therapeutics stock lower. Find out what’s next for PIPE-791 and MDD.
FDA lifts hold on Rein Therapeutics’ LTI-03 trial, reviving hopes for idiopathic pulmonary fibrosis treatment
FDA clears Rein Therapeutics to restart its Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, restoring investor confidence and trial momentum.
Can Calluna Pharma’s CAL101 finally change the game for idiopathic pulmonary fibrosis patients?
Calluna Pharma begins Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis, targeting S100A4 for a novel antifibrotic approach.
Trevi Therapeutics announces positive results for Haduvio in Phase 2b CORAL study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported a positive outcome from the planned sample size re-estimation…
Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP)…
Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant…
BMS-986278 succeeds in phase 2 idiopathic pulmonary fibrosis trial, says Bristol Myers Squibb
Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in…
Clinical-stage Redx Pharma, Jounce Therapeutics sign $425m merger deal
Redx Pharma, a UK-based clinical-stage biotechnology company, and Jounce Therapeutics, a Nasdaq-listed clinical-stage immunotherapy company, have agreed to…
GRI Bio, Vallon Pharmaceuticals to merge for advancing NKT cell regulators
GRI Bio, a privately held clinical stage biotech company, will merge with a wholly-owned subsidiary of Nasdaq-listed Vallon…
AbbVie acquires UK biotech company DJS Antibodies for $255m
AbbVie has acquired DJS Antibodies, a privately-held UK-based biotech company, in an all-cash transaction valued at approximately $255…